|
|
Profile
|
Delegates :
Yuto Takemoto |
|
Incorporated :
December 23 , 2019 |
Paid in Capital :
68 Million yen |
Employees :
6 人 |
Address :
1F, Nagono Campus, 2-14-1 Nagono, Nishi-ku AICHI
〒451-0042
|
TEL/FAX :
+81-52-990-3092 / |
URL：
https://quastella.com/ |
Attachment :
|
Mission/Background :
Quastella Inc. is a biotech startup originating from Nagoya University, with a mission of “Cells, for everyone.” The company aims to establish advanced quality control standards for cell-based industries by leveraging AI and data science technologies. In emerging fields such as regenerative medicine, drug discovery, and cultured food, stable and reproducible cell quality remains a major bottleneck. Quastella addresses this challenge by transforming traditionally subjective, experience-based evaluation into quantitative, data-driven quality control. By enabling reliable and scalable cell production, the company supports innovation across medical, food, and industrial sectors, accelerating the realization of next-generation cell-based industries. |
|
Technology & Business
|
Quastella develops AI-based image analysis technologies for cell quality evaluation. Its core product, “Cytometa,” analyzes label-free microscopic images of cultured cells and converts cellular conditions into quantitative data. This enables users to standardize quality control processes, reduce variability, and improve reproducibility in cell manufacturing. In addition to software solutions, the company provides PoC support and consulting services tailored to customers’ specific cell types, culture environments, and manufacturing processes. These services help implement optimized AI models and accelerate digital transformation (DX) in cell production workflows across regenerative medicine, biopharmaceuticals, and other industries.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Cytometa
|
Launched
|
AI system for quantitative cell quality analysis
|
Expand customer base and global markets
|
PoC Support
|
Launched
|
Implementation support for customized QA AI models
|
Increase partnerships
|
Cell Quality Consulting
|
Launched
|
Consulting on cell manufacturing QC processes
|
Expand project pipeline
|
|
|
|
|
|
|
|
|
|
Highlights
|
Quastella has successfully developed and deployed its AI-based cell quality management system “Cytometa” which is being adopted by regenerative medicine companies and cell processing facilities. In July 2025, the company raised approximately JPY 110 million to accelerate its business expansion. It has also been selected for regional deep-tech acceleration programs, strengthening its position as a leading biotech startup in Japan.
|
|
Hot news
|
Quastella is actively expanding the capabilities of its AI platform “Cytometa” and exploring opportunities for international market entry, particularly in Asia.
|
|
Alliance strategy
|
Quastella seeks collaboration with companies, research institutes, and partners in regenerative medicine, drug discovery, and cell-based food industries. The company is particularly interested in joint research, technology implementation, and co-development projects focused on improving cell quality control and manufacturing processes using AI. It welcomes opportunities to expand the adoption of its Cytometa platform and co-create next-generation cell manufacturing solutions.
|
|
|